[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Khyber Medical University Peshawar\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":306},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,47,74,104,135,161,188,214,242,281],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100625641","integrated-oral-care-intervention-for-xerostomia-in-diabetes-patients-100625641",false,"NCT07425275","Integrated Oral Care Intervention for Xerostomia in Diabetes Patients","The Impact of Integrated Oral Care Intervention Provided by Endocrinologists on Oral Health and Well-being in Diabetes Patients","IOCID","Inclusion Criteria:\n\n* Presence of a single stone in the renal pelvis.\n* Age less than 18 years.\n* No congenital or acquired urinary tract abnormalities.\n* No pre-existing chest diseases (e.g., chronic lung disease, pleural effusion).\n\nExclusion Criteria:\n\n* Patients with multiple kidney stones.\n* Calyceal stones (stones located specifically in a calyx).\n* Pelviureteric junction obstruction (PUJO).\n* Pelvic kidney (renal ectopia).","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","Diabetes patients commonly experience dry mouth also known as xerostomia which can affect eating speaking oral health and overall quality of life. This study evaluates whether simple oral care actions delivered by endocrinologists during routine diabetes clinic visits can improve dry mouth symptoms and oral health related quality of life. Endocrinologists will be trained to screen for dry mouth provide brief counseling prescribe saliva substitutes and refer patients to dental services when needed. Adult patients with diabetes and symptoms of dry mouth will be followed before and after the intervention to assess changes in xerostomia severity and oral health outcomes. The study will also explore barriers and facilitators to integrating oral health care into routine diabetes management in Pakistan.",[27,28],"Diabetes Mellitus","Diabetic Neuropathies",[30,31,32,33],"Diabetes mellitus","Oral health quality of life","Non communicable diseases","Integrated oral care","RECRUITING","2026-08-16",{"date":37,"type":38},"2026-08-18","ACTUAL",{"date":40,"type":38},"2026-08-01",{"date":42,"type":21},"2027-01-30",{"name":44,"class":45},"Khyber Medical University Peshawar","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100650506","effect-of-orlistat-on-metabolic-and-hormonal-features-in-women-with-polycystic-ovary-syndrome-pcos-a-randomized-controlled-clinical-trial-100650506","NCT07747909","Effect of Orlistat on Metabolic and Hormonal Features in Women With Polycystic Ovary Syndrome (PCOS): a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Females aged 18-45 years.\n* Diagnosis of polycystic ovary syndrome (PCOS) according to the Rotterdam Criteria (presence of any two of the following):\n* Oligomenorrhea or amenorrhea.\n* Clinical or biochemical hyperandrogenism.\n* Polycystic ovaries on ultrasonography.\n* Body mass index (BMI) between 18.5 and 35 kg\u002Fm² (Asian criteria).\n\nExclusion Criteria:\n\n* Current or recent use of oral contraceptives, ovulation induction medications, anti-obesity medications, cholesterol-lowering medications, or other therapies\u002Fsupplements known to affect insulin physiology or androgen metabolism (e.g., inositols, curcumin, lipoic acid, cinnamon, gymnemic, or other botanical extracts).\n* Women undergoing in vitro fertilization (IVF) treatment.\n* Known congenital adrenal hyperplasia, thyroid disorders, hyperprolactinemia, or diabetes mellitus.\n* Presence of severe renal or liver disease.\n* Menopausal, pregnant, or breastfeeding women.\n* Anti-Müllerian Hormone (AMH) \\\u003C 0.7 ng\u002FmL.","FEMALE","45 Years",{"count":56,"type":21},120,[24],"This randomized controlled clinical trial aims to evaluate the effect of orlistat on the metabolic and hormonal features of women with polycystic ovary syndrome (PCOS). Eligible women diagnosed with PCOS according to the Rotterdam criteria will be randomly assigned to receive either orlistat plus standard lifestyle advice or placebo plus standard lifestyle advice for three months. The study will assess the effect of orlistat on hormonal parameters, glucose metabolism, lipid profile, liver function, anthropometric measures, non-alcoholic fatty liver disease, and quality of life to determine its effectiveness as an adjunctive treatment for women with PCOS.",[60],"Polycystic Ovary Syndrome",[62,63,64,65],"PCOS","Orlistat","Lifestyle Intervention","Quality of Life","2026-07-31",{"date":68,"type":38},"2026-08-05",{"date":70,"type":38},"2026-01-01",{"date":72,"type":21},"2026-09-15",{"name":44,"class":45},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":91,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":46},"100648446","feasibility-of-a-culturally-adapted-nurse-led-cope-intervention-for-caregivers-of-children-with-autism-spectrum-disorder-100648446","NCT07722949","Feasibility of a Culturally Adapted Nurse-Led COPE Intervention for Caregivers of Children With Autism Spectrum Disorder","Feasibility of Culturally Adapted, Nurse-Led COPE Intervention on Psychological Wellbeing of Primary Caregivers of Child With Autism Spectrum Disorder (CASD)","COPE-ASD","Inclusion Criteria:\n\n* Male or female primary caregivers aged 18 years or older.\n* Primary caregiver of a child with a confirmed diagnosis of Autism Spectrum Disorder (ASD).\n* Able to communicate in Urdu.\n* Willing and able to provide written informed consent.\n* Available to attend all intervention sessions and follow-up assessments.\n\nExclusion Criteria:\n\n* Caregivers currently participating in another structured psychosocial, behavioral, or parenting intervention.\n* Caregivers with a diagnosed severe psychiatric illness or cognitive impairment that would interfere with participation.\n* Caregivers unable to communicate effectively in Urdu.\n* Caregivers who decline or are unable to provide informed consent.\n* Caregivers who are unavailable to complete the intervention or follow-up assessments.",{"count":83,"type":21},77,[24],"This study aims to evaluate the feasibility of a culturally adapted, nurse-led Creating Opportunities for Parent Empowerment (COPE) intervention to improve the psychological wellbeing of primary caregivers of children with Autism Spectrum Disorder (ASD) in Pakistan. The study will use an exploratory sequential mixed-methods design comprising a qualitative needs assessment followed by a pilot randomized controlled feasibility trial. Qualitative interviews will identify caregivers' training needs and inform the cultural adaptation of the COPE intervention. Eligible caregivers will then be randomly assigned to either an intervention group receiving the culturally adapted COPE program in addition to routine care or a control group receiving routine care alone. The intervention consists of four weekly nurse-led sessions focusing on psychoeducation, cognitive restructuring, coping strategies, positive parenting, emotional regulation, and family resilience. Psychological wellbeing will be assessed using the Depression Anxiety Stress Scale-21 (DASS-21) at baseline and one month after the intervention. The study will also evaluate recruitment, retention, intervention adherence, acceptability, and implementation feasibility to inform the design of a future definitive randomized controlled trial.",[87,88,89,90],"Autism Spectrum Disorder","Psychological Distress","Depression","Anxiety",[87,92,93,94,95],"Caregivers","Psychological Wellbeing","Feasibility Trial","Randomized controlled trial","2026-07-20",{"date":98,"type":38},"2026-07-23",{"date":100,"type":38},"2026-07-15",{"date":102,"type":21},"2027-05-25",{"name":44,"class":45},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},"100645471","phase-3-effect-of-psilocybin-and-structured-integrated-reframing-therapy-on-gut-brain-axis-biomarkers-and-depression-in-major-depressive-disorder-100645471","NCT07703722","Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder","Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18-60 years.\n* Diagnosis of Major Depressive Disorder (MDD) according to DSM-5 criteria.\n* Trauma-related depression with clinically significant trauma symptoms.\n* Hamilton Depression Rating Scale (HAM-D) score \\>16.\n* PTSD Checklist for DSM-5 (PCL-5) score \\>33.\n* Generalized Anxiety Disorder-7 (GAD-7) score \\>10.\n* Receiving a stable single SSRI antidepressant regimen for at least 6 weeks before enrollment with adequate treatment adherence.\n* Able and willing to provide written informed consent.\n* Willing to comply with all study procedures and follow-up visits.\n* Women of childbearing potential must agree to use effective contraception throughout the study.\n\nExclusion Criteria:\n\n* Significant cardiovascular disease.\n* Clinically significant hepatic or renal impairment.\n* Significant neurological disorders.\n* Current or past psychotic disorder or bipolar disorder.\n* Current substance or alcohol use disorder, including ketamine or psychedelic drug use.\n* Use of more than one antidepressant medication.\n* Pregnancy, planned pregnancy, or breastfeeding.\n* Known hypersensitivity or contraindication to psilocybin.\n* Participation in another interventional clinical trial within the previous 30 days.\n* Inability or unwillingness to provide informed consent.\n* Any medical or psychiatric condition that, in the investigator's opinion, would interfere with safe participation or study assessments.","60 Years",{"count":113,"type":21},60,[115],"PHASE3","Trauma-related Major Depressive Disorder (MDD) is frequently associated with poor response to conventional antidepressants, persistent psychological distress, and alterations in gut-brain axis function. Existing assessment tools primarily diagnose depression or PTSD but provide limited guidance for integrated clinical management. This study aims to develop and validate the Trauma Anxiety Depression Emotion (TADE) management tool while simultaneously evaluating the effectiveness of psilocybin-assisted Structured Integrated Reframing Therapy (SIRT) in improving clinical and biological outcomes.\n\nThis prospective, four-arm randomized controlled trial will compare conventional therapy, psilocybin therapy, SIRT, and psilocybin-assisted SIRT. Participants will undergo assessment using the newly developed TADE tool together with established psychometric scales including HAM-D, PCL-5, and GAD-7. Biological outcomes will include serum gut-brain axis and inflammatory biomarkers, including Short-Chain Fatty Acids (SCFAs), Interleukin-6 (IL-6), Interleukin-10 (IL-10), Zonulin, Occludin, and Glial Cell Line-Derived Neurotrophic Factor (GDNF). Assessments will be performed at baseline, during treatment, and at 12-week follow-up. The study aims to determine whether combining psilocybin with SIRT provides superior clinical improvement and favorable biological changes compared with either intervention alone while establishing the validity and clinical utility of the TADE management tool.",[118,119],"Major Depressive Disorder","Post-Traumatic Stress Disorder (PTSD)",[121,122,123,124,125],"Psilocybin","TADE Tool","Trauma","Biomarkers","Randomized Controlled Trial","2026-07-12",{"date":128,"type":38},"2026-07-14",{"date":130,"type":38},"2026-04-01",{"date":132,"type":21},"2027-11-22",{"name":44,"class":45},3,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":46},"100644271","effectiveness-of-neuroplasticity-targeted-supplements-on-neuroinflammatory-markers-adhd-symptom-severity-and-clinical-scores-in-children-100644271","NCT07665658","Effectiveness of Neuroplasticity-Targeted Supplements on Neuroinflammatory Markers, ADHD Symptom Severity, and Clinical Scores in Children","Effectiveness of Neuroplasticity-Targeted Supplements on Neuroinflammatory Markers, ADHD Symptom Severity, and Clinical Scores in Children: A Randomized Controlled Trial","Inclusion Criteria:\n\n* DSM-5 confirmed ADHD diagnosis\n* Age 6-12 years\n* Medication-free or on stable stimulant medication (≥1 month)\n\nExclusion Criteria:\n\n* Antibiotic use in last 4 weeks\n* Gastrointestinal disorders\n* Neurological comorbidities (e.g., epilepsy)\n* Severe food allergies","6 Years","12 Years",{"count":145,"type":21},68,[24],"This randomized controlled trial will evaluate the effectiveness of neuroplasticity-targeted supplements on neuroinflammatory markers and ADHD symptoms in children aged 6 to 12 years diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Participants will be randomly assigned to one of four groups: gut-targeted supplements (prebiotics and probiotics), brain-targeted supplements (omega-3 fatty acids and vitamin B1), combined supplementation, or placebo. The intervention period will last 12 weeks. Primary outcomes include changes in ADHD symptom severity and clinical scores using validated rating scales. Secondary outcomes include changes in biomarkers of neuroinflammation and neuroplasticity, including IL-6, TNF-alpha, BDNF, short-chain fatty acids, and Claudin-5.",[149],"Attention Deficit Hyperactivity Disorder",[149,125,151,152],"Neuroinflammation","Neuroplasticity","2026-06-22",{"date":155,"type":38},"2026-06-24",{"date":157,"type":38},"2026-03-01",{"date":159,"type":21},"2026-12-25",{"name":44,"class":45},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":168,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":185,"leadSponsor":187,"locationsCount":46},"100637010","efficacy-of-combining-mulligan-spinal-mobilization-with-leg-movement-and-mechanical-lumbar-traction-in-lumbar-radiculopathy-100637010","NCT07573124","Efficacy of Combining Mulligan Spinal Mobilization With Leg Movement and Mechanical Lumbar Traction in Lumbar Radiculopathy","Efficacy of Combining Mulligan's Spinal Mobilization With Leg Movement Technique and Mechanical Lumbar Traction Among Patients With Lumbar Radiculopathy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 20-50 years\n* Male and female participants\n* Unilateral radiculopathy due to L4-L5 or L5-S1 disc bulge, confirmed by clinical examination and MRI\n* Symptom duration of 4 weeks to 6 months\n* Positive Straight Leg Raise (SLR) test on the affected leg (\\\u003C70° of hip flexion)\n* Pain intensity \\\u003C7 on the Numeric Pain Rating Scale (NPRS; mild to moderate pain)\n\nExclusion Criteria:\n\n* Cognitive impairment, dementia, central cord signs\n* Inflammatory or degenerative spine conditions\n* Spine surgery within the last 6 months\n* Pregnant women in the later half of 2nd trimester or 3rd trimester\n* Muscular involvement (e.g., Deep Gluteal syndrome, Piriformis syndrome)\n* Currently receiving medications or other contemporaneous treatment","20 Years","50 Years",{"count":171,"type":21},32,[24],"Lumbar radiculopathy (LR), often caused by disc herniation, results in significant pain, disability, and reduced quality of life. Spinal Mobilization with Leg Movement (SMWLM) is a manual technique that has shown promise, while mechanical lumbar traction is used to reduce nerve compression, though its standalone effectiveness is debated. This randomized controlled trial aims to compare the combined effect of SMWLM plus mechanical lumbar traction against SMWLM alone, both administered with conventional physiotherapy. Outcomes will be assessed over 4 weeks to determine if the combined intervention offers superior pain relief, functional improvement, and range of motion in patients with unilateral L4-L5 or L5-S1 radiculopathy.",[175],"Lumbar Radiculopathy",[177,178,179,180,95],"Lumbar radiculopathy","Mulligan mobilization","Mechanical lumbar traction","Physical therapy","2026-05-01",{"date":183,"type":38},"2026-05-07",{"date":130,"type":38},{"date":186,"type":21},"2026-11-15",{"name":44,"class":45},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":195,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":46},"100635546","comparison-of-radiological-outcome-of-conventional-vs-accelerated-ponseti-casting-technique-for-treatment-of-club-foot-100635546","NCT07554092","Comparison of Radiological Outcome of Conventional vs Accelerated Ponseti Casting Technique for Treatment of Club Foot","Comparison of Radiological Outcome of Conventional vs Accelerated Ponseti Casting Technique for Treatment of Club Foot: Randomized Controlled Trial","Inclusion Criteria:\n\n-Both gender with idiopathic club foot with age less than 6 months\n\nExclusion Criteria:\n\n* Syndromic club foot (e.g., associated with arthrogryposis, myelomeningocele, or other genetic syndromes)\n* Previous treatment for club foot (either serial casting or surgical intervention)\n* Any other significant congenital anomaly or medical condition that, in the opinion of the investigator, would interfere with treatment or follow-up","1 Day","5 Months",{"count":198,"type":21},144,[24],"Club foot (congenital talipes equinovarus) is a common birth deformity affecting 1-2 per 1,000 live births, with even higher rates in low-income countries. The standard treatment is the Ponseti method using weekly serial casts, but weekly visits for several weeks can be challenging for families in hot climates or with limited resources. This randomized controlled trial compares the standard once-weekly Ponseti casting with an accelerated twice-weekly casting technique. The primary outcome is radiological correction measured by the lateral talocalcaneal angle (target ≥35°) on standardized foot X-rays taken six weeks after brace fitting. Secondary outcomes include the talocalcaneal index (\\>40) and the tibio-calcaneal (dorsiflexion) angle (60-90°). Babies under six months of age with idiopathic club foot will be randomly assigned to either the standard or accelerated casting group. All other aspects of the Ponseti method (manipulation, number of casts, tenotomy when needed, final cast for three weeks, and foot abduction orthosis) remain identical. Adverse events such as skin problems, swelling, or cast complications will be recorded. The study aims to determine whether accelerated casting achieves better radiographic correction without increasing risks.",[202],"Club Foot",[202,204,95,205],"Ponseti Casting Technique","Congenital talipes equinovarus","2026-04-21",{"date":208,"type":38},"2026-04-28",{"date":210,"type":38},"2026-02-01",{"date":212,"type":21},"2026-11-25",{"name":44,"class":45},{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":17,"minAge":221,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":226,"conditions":227,"keywords":231,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":239,"leadSponsor":241,"locationsCount":46},"100625639","impact-of-chewing-gum-on-postoperative-gut-motility-in-gastrointestinal-surgery-patients-100625639","NCT07425249","Impact of Chewing Gum on Postoperative Gut Motility in Gastrointestinal Surgery Patients","Impact of Chewing Gum on Postoperative Gut Motility in Gastrointestinal Surgery Patients: A Randomized Controlled Trial at Khyber Teaching Hospital, Peshawar, Pakistan","Inclusion Criteria:\n\n* Age between 17 and 85 years.\n* Patients of either gender.\n* Undergoing open gastrointestinal surgical procedures (elective or emergency).\n* Willing to participate and able to provide informed consent.\n\nExclusion Criteria:\n\n* Patients with metabolic or endocrine disorders (diabetes mellitus, hypothyroidism, or hyperthyroidism).\n* Patients with renal disease or electrolyte imbalance.\n* Patients with chronic constipation or neuromuscular disorders.\n* Patients with substance abuse or drug addiction.\n* Patients receiving medications affecting gut motility (calcium channel blockers or antiepileptic drugs).\n* Patients with dental prosthesis or undergoing laparoscopic gastrointestinal surgery.","17 Years","85 Years",{"count":224,"type":21},96,[24],"Postoperative ileus (POI) is a frequent complication after abdominal surgery, leading to delayed gastrointestinal motility, prolonged hospital stay, and increased patient discomfort. Chewing gum, as a form of sham feeding, has been proposed to stimulate gut motility through vagal stimulation and increased gastrointestinal secretions. This randomized controlled trial aims to assess the effect of chewing gum on early recovery of gastrointestinal motility in patients undergoing open gastrointestinal surgery.",[228,229,230],"Postoperative Ileus","Delayed Gastrointestinal Motility","Postoperative Gut Dysfunction",[228,232,233,234],"Gastrointestinal Motility","Enhanced Recovery After Surgery (ERAS)","Postoperative Recovery","2026-02-16",{"date":237,"type":38},"2026-02-20",{"date":70,"type":38},{"date":240,"type":21},"2026-10-29",{"name":44,"class":45},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":250,"sex":17,"minAge":195,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":254,"phases":4,"briefSummary":255,"conditions":256,"keywords":264,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":46},"100517522","impact-of-diet-and-nutrition-on-growth-and-development-in-young-children-100517522","NCT06018636","Impact of Diet and Nutrition on Growth and Development in Young Children","Dietary Intake\u002FPatterns, Nutritional Status and Their Association With Growth and Development of Children From Remote, Agropastoral Communities of District Swat, Pakistan","DIGEST","Inclusion Criteria:\n\n* Households living in the area from the last two 2 years.\n* Households having infants or young children ≤ years.\n* Households planning to reside in the same area for the next 1 year.\n\nExclusion Criteria:\n\n* Children with any co-existent systemic diseases, confirmed from medical records.\n* Children on continuous medications for any medical issue.\n* Physically or mentally handicapped children",true,"24 Months",{"count":253,"type":21},832,"OBSERVATIONAL","The association between nutrition in early life and its long-term health consequences has long been known. However, there is a scarcity of scientific evidence on how nutritional status affects child growth and development in remote, rural agro-pastoral communities with distinct dietary intake habits, geographical location, socio-economic status, and cultures.",[257,258,259,260,261,262,263],"Nutrition","Growth","Development","Stunting","Wasting","Obesity","Child Development",[265,266,258,267,268,269,270,271,272],"Nutritional status","Malnutrition","Cognitive Development","Anthropometry","Agropastoral","remote","rural","Urban","2026-01-06",{"date":275,"type":38},"2026-01-08",{"date":277,"type":38},"2023-06-28",{"date":279,"type":21},"2028-09-30",{"name":44,"class":45},{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":250,"sex":17,"minAge":168,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":22,"phases":290,"briefSummary":291,"conditions":292,"keywords":295,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":46},"100559207","engagement-of-community-through-participatory-learning-and-action-for-control-and-prevention-of-type-ii-diabetes-and-its-risk-factors-empower-d-100559207","NCT06561126","Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors [EMPOWER-D]","Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors [EMPOWER-D]: Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n* Individuals aged 20 years and above.\n* Participants residing in the rural areas of Peshawar and Swabi, Pakistan.\n* Individuals willing to participate in the study and provide consent.\n* Both individuals with normoglycemia, intermediate hyperglycemia, and diabetes are encouraged to participate.\n* Participants who can attend the scheduled meetings and interventions as per the study protocol.\n\nExclusion Criteria:\n\n* Individuals below the age of 20 years.\n* Individuals unwilling to provide consent for participation.\n* Participants with severe health conditions that may hinder their active involvement in the study.\n* Individuals with a history of non-compliance with medical interventions or research protocols",{"count":289,"type":21},12744,[24],"This project aims to adapt, implement, and evaluate Participatory Learning and Action (PLA) based intervention in rural areas of KPK, Pakistan which includes Peshawar and Swabi for TIIDM prevention and control. The pivotal components of this approach include adapting, implementing, and evaluating the PLA-based intervention for the prevention and control of Type II diabetes. These components will be tailored to meet the specific needs of two different settings in Peshawar and Swabi, Pakistan.\n\nType II Diabetes Mellitus (TIIDM) is considered the fastest-growing health emergency, affecting 537 million adults worldwide. Global projections for the year 2045 suggest that a 12.2% rise in TIIDM is anticipated with an additional 11.4% rise for intermediate hyperglycemia (IHG) \\[1\\]. Around 80% of people with TIIDM reside in low-and middle-income countries (LMICs), exhausting the already burdened healthcare system \\[2\\]. The intervention \"Community groups or mobile phone messaging to prevent and control type 2 diabetes and intermediate hyperglycemia in Bangladesh (DMagic)\" has been tested and found effective in the rural context of Bangladesh \\[1-3\\]. A full trial will be conducted in the rural areas of Peshawar and Swabi, Pakistan.\n\nIt is anticipated that with the use of evidence-based approaches, best practices, and meaningful community participation, PLA is expected to enhance social and behavioural determinants of health and subsequent outcomes. This will further pave the way for the control of other NCDs through a similar focused approach.",[293,294],"Type II Diabetes Mellitus","Intermediate Hyperglycemia (IHG)",[296,27,293,297],"Community-Based Participatory","Intermediate hyperglycemia","2025-08-29",{"date":300,"type":38},"2025-09-02",{"date":302,"type":38},"2025-05-01",{"date":304,"type":21},"2026-08-31",{"name":44,"class":45},""]